Clinical investigation of EGFR mutation detection by pyrosequencing in lung cancer patients

Kim,Hee  Joung; Oh,Seo  Young; Kim,Wan  Seop; Kim,Sun  Jong; Yoo,Gwang  Ha; Kim,Won  Dong; Lee,Kye  Young

doi:10.3892/ol.2012.950

Clinical investigation of EGFR mutation detection by pyrosequencing in lung cancer patients

Authors:
- Hee Joung Kim
- Seo Young Oh
- Wan Seop Kim
- Sun Jong Kim
- Gwang Ha Yoo
- Won Dong Kim
- Kye Young Lee
View Affiliations

Affiliations: Department of Internal Medicine, Konkuk University School of Medicine, Seoul 143-729, Republic of Korea, Department of Pathology, Konkuk University School of Medicine, Seoul 143-729, Republic of Korea
Published online on: October 1, 2012 https://doi.org/10.3892/ol.2012.950
Pages: 271-276

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Direct sequencing is the standard method for the detection of epidermal growth factor receptor (EGFR) mutations in lung cancer, however, its relatively low sensitivity limits its clinical use. Pyrosequencing is a bioluminometric, real-time non-electrophoretic DNA sequencing technique with a number of advantages compared with direct sequencing, including higher sensitivity, speed, automation and cost-effectiveness. Clinical specimens from 202 lung cancer patients were analyzed for EGFR mutations in exons 18, 19, 20 and 21 using the pyrosequencing method following genomic DNA extraction from paraffin-embedded tissue specimens. All clinical data and tumor specimens were obtained from the Konkuk University Hospital (Korea) between July 2006 and December 2008. The results and clinical responses to EGFR‑tyrosine kinase inhibitors (TKIs) were compared. Overall, EGFR mutation-positive rate was 26.7% (54/202). Activating EGFR mutations were observed more frequently in female (52.1 vs. 13.0%), non‑smoking (47.8 vs. 15.8%) and adenocarcinoma (35.2 vs. 5.2%) patients. However, significant numbers of EGFR mutation-positive patients were identified as male, former or current smokers and non-adenocarcinoma patients. The combinations of favorable clinicopathological factors, including female, non‑smoking and adenocarcinoma, were not identified to significantly increase the positive EGFR mutation rate (female, 52.1%; female and non-smoker, 52.6%; female, non-smoker and adenocarcinoma, 51.9%). The present findings indicate that EGFR mutation analysis is a highly useful method for the prediction of response to EGFR-TKI and the use of favorable clinicopathological factors to perform this analysis is not suitable. Exon 19 deletion was the most common mutation (63.6%) and exon 21 L858R substitution was measured at 32.7%. The exon 20 T790M mutation was identified in 1 patient prior to EGFR-TKI treatment. EGFR mutation status is associated with response to EGFR-TKI and the overall response rate in patients who have the activating EGFR mutation was 82.4 vs. 5.9% in patients with a wild‑type EGFR. The present study demonstrates that EGFR mutations analyzed by the pyrosequencing method are well correlated with clinicopathological parameters and that this method may be useful in the clinical practice.

View Figures

View References

1	Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
2	Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): open label, randomized phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
3	Sequist LV, Martins RG, Spigel D, et al: First-line gefitinib in patients with advanced non-small cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 26:2442–2449. 2008. View Article : Google Scholar : PubMed/NCBI
4	Rosell R, Viteri S, Molina MA, et al: Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer. Curr Opin Oncol. 22:112–120. 2010. View Article : Google Scholar : PubMed/NCBI
5	Kimura H, Kasahara K, Kawaishi M, et al: Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small cell lung cancer. Clin Cancer Res. 12:3915–3921. 2006. View Article : Google Scholar : PubMed/NCBI
6	Kimura H, Fujiwara Y, Sone T, et al: High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci. 97:642–648. 2006. View Article : Google Scholar : PubMed/NCBI
7	Molina-Vila MA, Bertran-Alamillo J, Reguart N, et al: A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thorac Oncol. 3:1224–1235. 2008. View Article : Google Scholar : PubMed/NCBI
8	Cohen V, Agulnik JS, Ang C, et al: Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer. Cancer. 111:4309–4317. 2010. View Article : Google Scholar : PubMed/NCBI
9	Kim HJ, Lee KY, Kim YC, et al: Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Lung Cancer. 75:321–325. 2012. View Article : Google Scholar
10	Lee KY, Kim HJ, Kim SJ, et al: PNA-Mediated PCR Clamping for the detection of EGFR mutations in non-small cell lung cancer. Tuberc Respir Dis. 69:271–278. 2010. View Article : Google Scholar
11	Kim HJ, Kim WS, Shin KC, et al: Comparative analysis of peptide nucleic acid (PNA)-mediated real-time PCR clamping and DNA direct sequencing for EGFR mutation detection. Tuberc Respir Dis. 70:21–27. 2011. View Article : Google Scholar
12	Pao W and Ladanyi M: Epidermal growth factor receptor mutation testing in lung cancer, searching for the ideal method. Clin Cancer Res. 13:4954–4955. 2007. View Article : Google Scholar : PubMed/NCBI
13	Langaee T and Ronaghi M: Genetic variation analyses by pyrosequencing. Mutat Res. 573:96–102. 2005. View Article : Google Scholar : PubMed/NCBI
14	Ahmadian A, Ehn M and Hober S: Pyrosequencing: history, biochemistry and future. Clin Chim Acta. 363:83–94. 2006. View Article : Google Scholar : PubMed/NCBI
15	Dufort S, Richard MJ and Fraipont F: Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues. Anal Biochem. 391:166–168. 2009. View Article : Google Scholar : PubMed/NCBI
16	Tsiatis AC, Norris-Kirby A, Rich RG, et al: Comparison of Sanger sequencing, pyrosequencing and melting curve analysis for the detection of KRAS mutations. J Mol Diagn. 12:425–432. 2010. View Article : Google Scholar : PubMed/NCBI
17	Kim SK, Kim DL, Han HS, et al: Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol. 17:118–125. 2008. View Article : Google Scholar : PubMed/NCBI
18	Inoue A, Kobayashi K, Usui K, et al: First-line gefitinib for patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 27:1394–1400. 2009. View Article : Google Scholar : PubMed/NCBI
19	Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
20	Ettinger DS, Akerley W, Bepler G, et al: Non-small cell lung cancer. J Natl Compr Canc Netw. 8:740–801. 2010.PubMed/NCBI
21	Pirker R, Herth FJ, Kerr KM, et al: Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol. 5:1706–1713. 2010. View Article : Google Scholar : PubMed/NCBI
22	Ronaghi M: Pyrosequencing sheds light on DNA sequencing. Genome Res. 11:3–11. 2001. View Article : Google Scholar : PubMed/NCBI
23	Ogino S, Kawasaki T, Brahmandam M, et al: Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn. 7:413–421. 2005. View Article : Google Scholar : PubMed/NCBI
24	Uhlmann K, Brinckmann A, Toliat MR, et al: Evaluation of a potential epigenetic biomarker by quantitative methyl-single nucleotide polymorphism analysis. Electrophoresis. 23:4072–4079. 2002. View Article : Google Scholar : PubMed/NCBI
25	Tost J, Dunker J and Gut IG: Analysis and quantification of multiple methylation variable positions in CpG islands by pyrosequencing. Biotechniques. 35:152–156. 2003.PubMed/NCBI
26	Forbes SA, Bharma G, Bamford S, et al: The catalogue of somatic mutations in cancer (COSMIC). Curr Protoc Hum Genet Chapter 10: unit 10.11. 2008. View Article : Google Scholar
27	Rekhtman N, Brandt SM, Sigel CS, et al: Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: High accuracy of tumor subtyping and feasibility of EGR and KRAS molecular testing. J Thor Oncol. 6:451–458. 2011. View Article : Google Scholar : PubMed/NCBI
28	Tokumo M, Toyooka S, Kiura K, et al: The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res. 11:1167–1173. 2005.PubMed/NCBI
29	Shigematsu H, Lim L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI